These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 19528803)

  • 21. Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?
    Mir MH; Changal KH; Aziz SA; Bhat GM; Lone AR
    Int Urol Nephrol; 2016 Nov; 48(11):1811-1816. PubMed ID: 27448573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib.
    Di Fiore F; Rigal O; Ménager C; Michel P; Pfister C
    Br J Cancer; 2011 Dec; 105(12):1811-3. PubMed ID: 22095228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Newly approved therapies for RCC and their effect on the standard of care.
    Figlin RA
    Clin Adv Hematol Oncol; 2007 Jan; 5(1):35-6, 66. PubMed ID: 17339824
    [No Abstract]   [Full Text] [Related]  

  • 24. Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
    Bukowski RM
    Clin Genitourin Cancer; 2009 Jan; 7(1):9-10. PubMed ID: 19213661
    [No Abstract]   [Full Text] [Related]  

  • 25. Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.
    Kitajima K; Takahashi S; Maeda T; Yoshikawa T; Ohno Y; Fujii M; Miyake H; Fujisawa M; Sugimura K
    Eur J Radiol; 2012 Sep; 81(9):2060-5. PubMed ID: 21724350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
    Hiles JJ; Kolesar JM
    Am J Health Syst Pharm; 2008 Jan; 65(2):123-31. PubMed ID: 18192256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring the role of novel agents in the treatment of renal cell carcinoma.
    Maluf FC; Fernandes Gdos S; Kann AG; Aguilar-Ponce JL; de la Garza J; Buzaid AC
    Cancer Treat Rev; 2008 Dec; 34(8):750-60. PubMed ID: 18801619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
    Schmidinger M; Vogl UM; Bojic M; Lamm W; Heinzl H; Haitel A; Clodi M; Kramer G; Zielinski CC
    Cancer; 2011 Feb; 117(3):534-44. PubMed ID: 20845482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
    Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
    J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
    [No Abstract]   [Full Text] [Related]  

  • 30. An update on the medical therapy of advanced metastatic renal cell carcinoma.
    Kruck S; Merseburger AS; Gakis G; Kramer MW; Stenzl A; Kuczyk MA
    Scand J Urol Nephrol; 2008; 42(6):501-6. PubMed ID: 18615363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.
    Loriot Y; Boudou-Rouquette P; Billemont B; Ropert S; Goldwasser F
    Ann Oncol; 2008 Nov; 19(11):1975. PubMed ID: 18723549
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.
    Strumberg D
    J Clin Oncol; 2008 Jul; 26(20):3469-71; author reply 2471. PubMed ID: 18612169
    [No Abstract]   [Full Text] [Related]  

  • 33. [New therapeutic regimes in metastasic renal-cell carcinoma].
    Bierer S; Hertle L; Nitschmann S
    Internist (Berl); 2008 Jan; 49(1):114-7. PubMed ID: 18704353
    [No Abstract]   [Full Text] [Related]  

  • 34. Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
    Martin B; Edeline J; Patard JJ; Oger E; Jouan F; Boulanger G; Zerrouki S; Vigneau C; Rioux-Leclercq N
    J Cancer Res Clin Oncol; 2012 Jun; 138(6):907-16. PubMed ID: 22322364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two new drugs for renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Feb; 49(1255):18-20. PubMed ID: 17325624
    [No Abstract]   [Full Text] [Related]  

  • 36. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
    Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
    J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
    Kondo T
    Nihon Jinzo Gakkai Shi; 2012; 54(5):574-80. PubMed ID: 22991835
    [No Abstract]   [Full Text] [Related]  

  • 38. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
    Daimon M; Kato T; Kaino W; Takase K; Karasawa S; Wada K; Kameda W; Susa S; Oizumi T; Tomita Y; Kato T
    Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.
    Riesenbeck LM; Bierer S; Hoffmeister I; Köpke T; Papavassilis P; Hertle L; Thielen B; Herrmann E
    World J Urol; 2011 Dec; 29(6):807-13. PubMed ID: 21153827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K; Bergmann L; Gschwend J; Keilholz U
    Aktuelle Urol; 2011 Jul; 42(4):242-6. PubMed ID: 21720974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.